Experience with pneumococcal conjugate vaccine in Norway.
Seven-valent pneumococcal conjugate vaccine (PCV7) was introduced into the Norwegian childhood vaccination program in July 2006 in a 2+1 dose (three-dose) schedule. Vaccine coverage quickly reached high levels and the incidence rate of invasive pneumococcal disease in children under 2 years of age declined rapidly. The vaccine program's effectiveness was estimated to be 74%.
Aaberge
Ingeborg S
IS
Department Director, Department of Bacteriology & Immunology, Division of Infectious Disease Control, Norwegian Institute of Public Health, PO Box 4404, Nydalen, NO-0403 Oslo, Norway. ingeborg.aaberge@fhi.no
D002648:Child; D002675:Child, Preschool; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D006801:Humans; D007114:Immunization / Q000379:methods; D017589:Immunization Programs; D007117:Immunization, Secondary; D015994:Incidence; D007223:Infant; D009664:Norway / Q000453:epidemiology; D011008:Pneumococcal Infections / Q000453:epidemiology* / Q000382:microbiology / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000276:immunology*
D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D022242:Pneumococcal Vaccines